Recombinant Immunogens Designed by AI Epitope Prioritization Confer Protection Against Mycobacterium tuberculosis
Vaccines · 01.05.2026 · 14 (5) · 408
DOI: 10.3390/vaccines14050408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 01.05.2026. Verfasst von Ning Fang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Pudong Hospital and School of Life Sciences, State Key Laboratory of Genetics and Development of Complex Phenotypes, Shanghai Engineering Re…. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Project of China, Shanghai Committee of Science and Technology.
Abstract (Originalsprache)
Background
Tuberculosis (TB) remains a major global health challenge, highlighting the urgent need for more effective vaccines. This study aimed to develop an artificial intelligence-guided epitope prediction and prioritization pipeline to identify immunodominant peptides from Mycobacterium tuberculosis (Mtb) and to evaluate the immunogenicity and protective efficacy of the resulting vaccine candidates.
Methods
An AI-guided framework was used to predict and prioritize immunodominant Mtb epitopes, leading to the generation of 72 recombinant immunogens. Among these, RI-13, RI-20, and RI-31 were selected as the leading candidates. Their protective efficacy was assessed in a zebrafish TB infection model and in BALB/c mice following DNA vaccination. Humoral and cellular immune responses were further evaluated in C57BL/6 mice.
Results
RI-13, RI-20, and RI-31 markedly reduced infection-associated pathology and lowered bacterial burden by up to 1.5 log10 in the zebrafish TB infection model, outperforming benchmark antigen combinations, including the Ag85A plus ESAT6/CFP10 cocktail used in the phase III vaccine candidate GamTBvac. In BALB/c mice, DNA vaccination with each construct reduced pulmonary mycobacterial burden by approximately 0.3 log10 and alleviated lung tissue damage. In addition, all three candidates elicited robust humoral and cellular immune responses, with RI-13 showing the strongest overall immunogenicity and inducing a balanced Th1, Th2, and Th17 response profile in C57BL/6 mice.
Conclusions
These findings identify RI-13, derived from Rv1174c, as a promising next-generation TB vaccine candidate. More broadly, this study supports the utility of an AI-guided framework for the rational design and preclinical prioritization of novel TB immunogens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanghai Pudong Hospital and School of Life Sciences, State Key Laboratory of Genetics and Development of Complex Phenotypes, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Shanghai…
- School of Life Sciences, State Key Laboratory of Genetics and Development of Complex Phenotypes, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Shanghai 200438, China.
- College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, China.
- Shanghai Institute of Infectious Diseases and Biosecurity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
- State Key Laboratory for Animal Disease Control and Prevention, Lanzhou Center for Tuberculosis Research, Institute of Pathogen Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
- Shanghai Institute of Immunology, Shanghai Jiao Tong University, Shanghai 200025, China.
ORCID-Profile: Decheng Wang, Zhidong Hu, Xiaoyong Fan, Bingdong Zhu, Lu Zhang, Jixi Li
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Project of China
- Shanghai Committee of Science and Technology
Zitieren
APA
Fang, N., Chen, A., Zhang, Z., Ye, M., Pan, J., Huang, W., Wang, D., Hu, Z., Fan, X., Zhu, B., Wang, Y., Zhao, G., Zhang, L., & Li, J. (2026). Recombinant Immunogens Designed by AI Epitope Prioritization Confer Protection Against Mycobacterium tuberculosis. Vaccines, 14(5), 408. https://doi.org/10.3390/vaccines14050408
Vancouver
Fang N, Chen A, Zhang Z, Ye M, Pan J, Huang W, et al. Recombinant Immunogens Designed by AI Epitope Prioritization Confer Protection Against Mycobacterium tuberculosis. Vaccines. 2026;14(5):408. doi:10.3390/vaccines14050408
BibTeX
@article{Fang2026,
author = {Fang, Ning and Chen, Anke and Zhang, Zhifei and Ye, Menglin and Pan, Jiasong and Huang, Weili and Wang, Decheng and Hu, Zhidong and Fan, Xiaoyong and Zhu, Bingdong and Wang, Ying and Zhao, Guoping and Zhang, Lu and Li, Jixi},
title = {Recombinant Immunogens Designed by AI Epitope Prioritization Confer Protection Against Mycobacterium tuberculosis},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {5},
pages = {408},
doi = {10.3390/vaccines14050408}
}
EUVIMED